TrialClinical drug investigation2023

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.

Geert D'Haens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.